Evaluation of the mechanism underlying melatonin action in cholestatic liver disease treatment via network pharmacology, molecular docking, and in vivo experiments
PLOS One · 2026
DOI: 10.1371/journal.pone.0342978 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Tao Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Baotou Medical College, Baotou, China. Hauptthemen laut MEDLINE: Melatonin, Cholestasis. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Innovation Team Development Plan of Baotou Medical College, Public Hospital Research Joint Fund Science and Technology Project.
Abstract (Originalsprache)
The aim of this study was to investigate the mechanism underlying the action of melatonin (MT) in treating cholestatic liver disease. Melatonin and therapeutic targets for cholestatic liver disease were screened. A protein–protein interaction network was constructed using intersecting targets. Core targets were subjected to GO and KEGG enrichment analyses. We evaluated core target affinity through molecular docking. Biochemical indicators were measured in a mouse model of cholestasis to determine the pathological changes in liver tissue. The expression of core targets (MMP9, EGFR, and AKT) was detected through western blotting. The core targets for treating cholestatic liver disease included ALB, AKT1, ESR1, CASP3, PPARG, MMP9, PTGS2, SRC, EGFR, and IGF1. The biological processes included lipopolysaccharide stress response, bacterial molecular response, nutrient level response, and regulation of inflammatory response. Additionally, the estrogen, tumor necrosis factor-alpha, and VEGF signaling pathways were enriched in cholestatic liver disease. Molecular docking showed that MT had a strong binding affinity for MMP9, EGFR, and AKT1. Animal experiments demonstrated that melatonin alleviated inflammation and fibrosis in cholestatic liver disease, downregulated MMP9 expression, and upregulated the expression of EGFR, AKT, and phosphorylated AKT. Network pharmacology predictions suggested that these targets are closely associated with the estrogen signaling pathway. In conclusion, the protective effect of melatonin against cholestatic liver injury is likely mediated through the downregulation of MMP9 and upregulation of EGFR/AKT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate School of Baotou Medical College, Baotou, China.
- The Second Affiliated Hospital of Baotou Medical College, Baotou, China.
ORCID-Profile: Wang Jing
Förderung
- the Innovation Team Development Plan of Baotou Medical College
- Public Hospital Research Joint Fund Science and Technology Project
Zitieren
APA
Li, T., ZhenYu, J., & Jing, W. (2026). Evaluation of the mechanism underlying melatonin action in cholestatic liver disease treatment via network pharmacology, molecular docking, and in vivo experiments. PLOS One. https://doi.org/10.1371/journal.pone.0342978
Vancouver
Li T, ZhenYu J, Jing W. Evaluation of the mechanism underlying melatonin action in cholestatic liver disease treatment via network pharmacology, molecular docking, and in vivo experiments. PLOS One. 2026. doi:10.1371/journal.pone.0342978
BibTeX
@article{Li2026,
author = {Li, Tao and ZhenYu, Jiang and Jing, Wang},
title = {Evaluation of the mechanism underlying melatonin action in cholestatic liver disease treatment via network pharmacology, molecular docking, and in vivo experiments},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0342978}
}
EUVIMED